Mechanistically, the presence of the tumor induced a fraction of endogenously activated, OVA-specific CD8+ T cells, which may have led to an advantage in epitope competition over the smaller VSV-N-specific CD8+ T cell precursor pool [49]. The gene discussed is CD8A; the disease is neoplasm.